EUR 11.7
(-2.5%)
Year | Total Assets | Total Assets Growth |
---|---|---|
2023 | 14.91 Million EUR | -12.69% |
2022 | 17.08 Million EUR | -0.16% |
2021 | 17.1 Million EUR | -0.92% |
2020 | 17.26 Million EUR | 24.33% |
2019 | 13.88 Million EUR | 109139.65% |
2018 | 12.71 Thousand EUR | 29.73% |
2017 | 9799.68 EUR | 0.03% |
2016 | 9797.16 EUR | -6.17% |
2015 | 10.44 Thousand EUR | 89.55% |
2014 | 5508.44 EUR | -99.87% |
2013 | 4.25 Million EUR | 20.23% |
2012 | 3.53 Million EUR | 0.0% |
Year | Total Assets | Total Assets Growth |
---|---|---|
2023 FY | 14.91 Million EUR | -12.69% |
2023 Q4 | 14.91 Million EUR | 0.0% |
2023 Q2 | 14.3 Million EUR | 0.0% |
2022 FY | 17.08 Million EUR | -0.16% |
2022 Q2 | 15.95 Million EUR | 0.0% |
2022 Q4 | 17.08 Million EUR | 0.0% |
2021 Q4 | 17.1 Million EUR | 0.0% |
2021 FY | 17.1 Million EUR | -0.92% |
2021 Q2 | 16.35 Million EUR | 0.0% |
2020 Q2 | 14.84 Million EUR | 0.0% |
2020 FY | 17.26 Million EUR | 24.33% |
2020 Q4 | 14.81 Million EUR | 0.0% |
2019 Q2 | 12.73 Million EUR | 0.0% |
2019 FY | 13.88 Million EUR | 109139.65% |
2019 Q4 | 13.88 Million EUR | 0.0% |
2018 Q2 | 10.66 Thousand EUR | 0.0% |
2018 FY | 12.71 Thousand EUR | 29.73% |
2018 Q4 | 12.71 Thousand EUR | 0.0% |
2017 Q2 | 9632.78 EUR | 0.0% |
2017 FY | 9799.68 EUR | 0.03% |
2017 Q4 | 9799.68 EUR | 0.0% |
2016 Q2 | 9817.27 EUR | 0.0% |
2016 FY | 9797.16 EUR | -6.17% |
2016 Q4 | 9797.16 EUR | 0.0% |
2015 FY | 10.44 Thousand EUR | 89.55% |
2015 Q4 | 10.44 Thousand EUR | 0.0% |
2015 Q2 | 11.17 Thousand EUR | 0.0% |
2014 Q4 | 5508.44 EUR | 0.0% |
2014 Q2 | 5134.37 EUR | 0.0% |
2014 FY | 5508.44 EUR | -99.87% |
2013 FY | 4.25 Million EUR | 20.23% |
2013 Q4 | 4.25 Million EUR | 0.0% |
2012 FY | 3.53 Million EUR | 0.0% |
Name | Total Assets | Total Assets Difference |
---|---|---|
ABIONYX Pharma SA | 14.71 Million EUR | -1.38% |
ABIVAX Société Anonyme | 327.06 Million EUR | 95.44% |
Adocia SA | 24.95 Million EUR | 40.243% |
Aelis Farma SA | 26.28 Million EUR | 43.256% |
Biophytis S.A. | 11.93 Million EUR | -24.941% |
Advicenne S.A. | 12.4 Million EUR | -20.198% |
genOway Société anonyme | 31.84 Million EUR | 53.166% |
IntegraGen SA | 8 Million EUR | -86.403% |
Medesis Pharma S.A. | 1.92 Million EUR | -674.161% |
Neovacs S.A. | 47.53 Million EUR | 68.627% |
NFL Biosciences SA | 3.97 Million EUR | -275.581% |
Quantum Genomics Société Anonyme | 3.74 Million EUR | -298.021% |
Sensorion SA | 46.49 Million EUR | 67.925% |
Theranexus Société Anonyme | 7.23 Million EUR | -106.044% |
TME Pharma N.V. | 2.49 Million EUR | -498.672% |
Valbiotis SA | 33.24 Million EUR | 55.146% |
TheraVet SA | 7.53 Million EUR | -97.937% |
Valerio Therapeutics Société anonyme | 35.27 Million EUR | 57.723% |
argenx SE | 4.11 Billion EUR | 99.637% |
BioSenic S.A. | 9.55 Million EUR | -56.009% |
Celyad Oncology SA | 16.28 Million EUR | 8.409% |
DBV Technologies S.A. | 165.65 Million USD | 90.997% |
Galapagos NV | 4.35 Billion EUR | 99.658% |
Genfit S.A. | 173.87 Million EUR | 91.423% |
GeNeuro SA | 6.31 Million EUR | -136.229% |
Hyloris Pharmaceuticals SA | 47.68 Million EUR | 68.724% |
Innate Pharma S.A. | 184.19 Million EUR | 91.904% |
Inventiva S.A. | 69.13 Million EUR | 78.431% |
MaaT Pharma SA | 42.93 Million EUR | 65.263% |
MedinCell S.A. | 36.94 Million EUR | 59.638% |
Nanobiotix S.A. | 93.89 Million EUR | 84.118% |
Onward Medical N.V. | 43.62 Million EUR | 65.819% |
Oryzon Genomics S.A. | 106.9 Million EUR | 86.05% |
OSE Immunotherapeutics SA | 81.9 Million EUR | 81.791% |
Oxurion NV | 6.55 Million EUR | -127.678% |
Pharming Group N.V. | 426.33 Million EUR | 96.502% |
Poxel S.A. | 4.82 Million EUR | -209.204% |
GenSight Biologics S.A. | 9.08 Million EUR | -64.113% |
Transgene SA | 45.21 Million EUR | 67.019% |
Financière de Tubize SA | 1.92 Billion EUR | 99.223% |
UCB SA | 15.53 Billion EUR | 99.904% |
Valneva SE | 469.39 Million EUR | 96.823% |
Vivoryon Therapeutics N.V. | 30.82 Million EUR | 51.627% |